Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
1.
Digestion ; 89(3): 201-8, 2014.
Artigo em Inglês | MEDLINE | ID: mdl-24803137

RESUMO

BACKGROUND AND AIMS: Infliximab (IFX) is a monoclonal antibody used to treat patients with Crohn's disease (CD). Intra-abdominal abscess formation is a major complication of CD with negative effects on patient prognosis. We have analyzed risk factors for abscess formation in CD patients treated with IFX. METHODS: CD patients who received IFX between January 2000 and April 2011 at Keio University Hospital were analyzed retrospectively. Risk factors for abscess formation were assessed by univariate and multivariate logistic regression analyses. RESULTS: Intra-abdominal abscess was seen in 15 of 258 patients. Univariate analyses showed serum C-reactive protein (CRP) concentration at 14 weeks after initiation of IFX (p = 0.021), serum albumin concentration at week 0 (p = 0.022) and week 14 (p = 0.004), the presence of anal lesions (p = 0.036), progression of intestine deformation (p = 0.015) and early loss of response to IFX (p < 0.0001) to be risk factors. Multivariate analysis showed that CRP concentration at 14 weeks [odds ratio (OR) 1.361] and loss of IFX response within 6 months (OR 5.361) were independent risk factors. CONCLUSIONS: Abscess formation should be suspected in patients with symptoms of CD recurrence during IFX therapy. Uncontrolled CRP concentration and early loss of response to IFX are risk factors.


Assuntos
Abscesso Abdominal/etiologia , Anticorpos Monoclonais/uso terapêutico , Doença de Crohn/complicações , Doença de Crohn/tratamento farmacológico , Fator de Necrose Tumoral alfa/antagonistas & inibidores , Abscesso Abdominal/epidemiologia , Abscesso Abdominal/cirurgia , Proteína C-Reativa/análise , Progressão da Doença , Feminino , Humanos , Infliximab , Masculino , Estudos Retrospectivos , Medição de Risco , Fatores de Risco
2.
J Crohns Colitis ; 7(12): e609-14, 2013 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-23680174

RESUMO

BACKGROUND: Oral administration of tacrolimus is an effective remission induction therapy for steroid-refractory/dependent ulcerative colitis (UC). AIM: This study aimed to evaluate the short- as well as medium- and long-term effectiveness of tacrolimus therapy. METHODS: The medical records of 51 patients treated with tacrolimus for UC at our hospital between July 2009 and December 2011 were reviewed retrospectively. Clinical remission and improvement were defined as a Lichtiger score of 4 or less and as a Lichtiger score of ≤10 and a reduction in the score of ≥3 compared with the baseline score, respectively. Endoscopic findings were evaluated based on the endoscopic activity index and Mayo endoscopic score. RESULTS: The clinical effectiveness combining clinical remission and improvement was observed in 62.7% of the patients at 3 months. Thirty-six patients underwent colonoscopy at 3 months, and 12 (33.3%) and 10 patients (27.8%) showed Mayo endoscopic scores of 0 and 1, respectively. On Kaplan-Meier analysis, the overall percentage of event-free survivors, who did not require colectomy nor switching to other induction therapy such as infliximab, was 73.0% at 6 months, 49.9% at 1 year, and 37.8% at 2 years. Patients with a Mayo endoscopic score of 0-1 at 3 months showed significantly better medium- and long-term prognosis than those with a score of 2-3 (p<0.01). All adverse events, including infections in 2 patients, were reversible. CONCLUSIONS: Tacrolimus therapy was effective for inducing clinical and endoscopic remission of steroid-refractory/dependent UC. Endoscopic improvement was associated with favorable medium- and long-term prognosis.


Assuntos
Colite Ulcerativa/tratamento farmacológico , Imunossupressores/uso terapêutico , Mucosa Intestinal/patologia , Tacrolimo/uso terapêutico , Cicatrização , Administração Oral , Adolescente , Adulto , Idoso , Anti-Inflamatórios/uso terapêutico , Colite Ulcerativa/patologia , Colonoscopia , Intervalo Livre de Doença , Resistência a Medicamentos , Feminino , Humanos , Imunossupressores/administração & dosagem , Masculino , Pessoa de Meia-Idade , Indução de Remissão , Estudos Retrospectivos , Índice de Gravidade de Doença , Esteroides/uso terapêutico , Tacrolimo/administração & dosagem , Fatores de Tempo , Adulto Jovem
3.
Immunology ; 139(1): 19-29, 2013 May.
Artigo em Inglês | MEDLINE | ID: mdl-23566200

RESUMO

Bile acids (BAs) play important roles not only in lipid metabolism, but also in signal transduction. TGR5, a transmembrane receptor of BAs, is an immunomodulative factor, but its detailed mechanism remains unclear. Here, we aimed to delineate how BAs operate in immunological responses via the TGR5 pathway in human mononuclear cell lineages. We examined TGR5 expression in human peripheral blood monocytes, several types of in vitro differentiated macrophages (Mϕs) and dendritic cells. Mϕs differentiated with macrophage colony-stimulating factor and interferon-γ (Mγ-Mϕs), which are similar to the human intestinal lamina propria CD14(+) Mϕs that contribute to Crohn's disease (CD) pathogenesis by production of pro-inflammatory cytokines, highly expressed TGR5 compared with any other type of differentiated Mϕ and dendritic cells. We also showed that a TGR5 agonist and two types of BAs, deoxycholic acid and lithocholic acid, could inhibit tumour necrosis factor-α production in Mγ-Mϕs stimulated by commensal bacterial antigen or lipopolysaccharide. This inhibitory effect was mediated by the TGR5-cAMP pathway to induce phosphorylation of c-Fos that regulated nuclear factor-κB p65 activation. Next, we analysed TGR5 levels in lamina propria mononuclear cells (LPMCs) obtained from the intestinal mucosa of patients with CD. Compared with non-inflammatory bowel disease, inflamed CD LPMCs contained more TGR5 transcripts. Among LPMCs, isolated CD14(+) intestinal Mϕs from patients with CD expressed TGR5. In isolated intestinal CD14(+) Mϕs, a TGR5 agonist could inhibit tumour necrosis factor-α production. These results indicate that TGR5 signalling may have the potential to modulate immune responses in inflammatory bowel disease.


Assuntos
Doença de Crohn/imunologia , Citocinas/imunologia , Regulação da Expressão Gênica/imunologia , Mucosa Intestinal/imunologia , Macrófagos/imunologia , Receptores Acoplados a Proteínas G/imunologia , Transdução de Sinais/imunologia , Antígenos de Bactérias/imunologia , Antígenos de Bactérias/metabolismo , Células Cultivadas , Colagogos e Coleréticos/farmacologia , Doença de Crohn/metabolismo , Doença de Crohn/patologia , Doença de Crohn/terapia , Citocinas/biossíntese , Células Dendríticas/imunologia , Células Dendríticas/metabolismo , Células Dendríticas/patologia , Ácido Desoxicólico/farmacologia , Detergentes/farmacologia , Feminino , Regulação da Expressão Gênica/efeitos dos fármacos , Humanos , Interferon gama/farmacologia , Mucosa Intestinal/metabolismo , Mucosa Intestinal/patologia , Lipopolissacarídeos/farmacologia , Ácido Litocólico/farmacologia , Fator Estimulador de Colônias de Macrófagos/farmacologia , Macrófagos/metabolismo , Macrófagos/patologia , Masculino , Monócitos/imunologia , Monócitos/metabolismo , Monócitos/patologia , Proteínas Proto-Oncogênicas c-fos/imunologia , Proteínas Proto-Oncogênicas c-fos/metabolismo , Receptores Acoplados a Proteínas G/antagonistas & inibidores , Receptores Acoplados a Proteínas G/biossíntese , Transdução de Sinais/efeitos dos fármacos , Fator de Transcrição RelA/imunologia , Fator de Transcrição RelA/metabolismo
4.
Pathol Int ; 62(9): 577-82, 2012 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-22924843

RESUMO

Primary splenic lymphoma is rare, but malignant lymphoma often produces a lesion in the spleen as part of systemic disease. The frequency of splenic malignant lymphoma in Japan is unknown. We classified 184 specimens of the spleen according to the World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th edition (2008). Of the 184 specimens, 115 were determined to be lymphoid neoplasm (62.5%). The most common subtype of lymphoid neoplasm was diffuse large B-cell lymphoma (DLBCL) (46 cases), followed by splenic marginal zone lymphoma (SMZL) (28 cases), follicular lymphoma (11 cases), splenic B-cell lymphoma, unclassifiable (SBL-U) (6 cases) and peripheral T-cell lymphoma, not otherwise specified (4 cases). In the SBL-U subtype, 5 of 6 cases were splenic diffuse red pulp small B-cell lymphoma, and one case was the hairy cell leukemia variant. Analysis of clinical features revealed that patients with DLBCL had a higher age, high lactate dehydrogenase and tumor formation in the spleen. On the other hand, it was found that patients with SMZL had splenomegaly but no discrete tumor formation. Most of the patients with SBL-U presented with thrombocytopenia, bone marrow involvement, and advanced stage. Our study revealed the frequency and clinical features of splenic malignant lymphoma in Japan.


Assuntos
Linfoma não Hodgkin/patologia , Neoplasias Esplênicas/patologia , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Criança , Pré-Escolar , Feminino , Humanos , Lactente , Japão/epidemiologia , Linfoma não Hodgkin/classificação , Linfoma não Hodgkin/epidemiologia , Masculino , Pessoa de Meia-Idade , Esplenectomia , Neoplasias Esplênicas/classificação , Neoplasias Esplênicas/epidemiologia , Esplenomegalia/diagnóstico , Organização Mundial da Saúde , Adulto Jovem
5.
Gut Liver ; 6(3): 339-43, 2012 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-22844562

RESUMO

BACKGROUND/AIMS: In capsule endoscopy (CE), the capsule does not always reach the cecum within its battery life, which may reduce its diagnostic yield. We evaluated the effect of mosapride citrate, a 5-hydroxytryptamine-4 agonist that increases gastrointestinal motility, on CE completion. METHODS: In a retrospective study, we performed univariate and multivariate analyses for 232 CE procedures performed at our hospital. To identify factors that affect CE completion, the following data were systematically collected: gender, age, gastric transit time (GTT), nonsteroidal anti-inflammatory drug administration, previous abdominal surgery, hospitalization, use of a polyethylene glycol solution, use of mosapride citrate (10 mg), body mass index (BMI), and total recording time. RESULTS: The univariate analysis showed that oral mosapride citrate, GTT, and BMI were associated with improved CE completion. Multivariate analyses showed that oral mosapride citrate (odds ratio [OR], 1.99; 95% confidence interval [CI], 1.01 to 3.91) and GTT (OR, 2.34; 95% CI, 1.13 to 4.87) were significant factors for improving the CE completion. Oral mosapride citrate significantly shortened the GTT and small bowel transit time (SBTT). CONCLUSIONS: Oral mosapride citrate reduced the GTT and SBTT during CE and improved the CE completion rate.

6.
J Gastroenterol Hepatol ; 27(10): 1617-22, 2012 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-22646064

RESUMO

BACKGROUND AND AIM: In Japan, patient acceptance of bowel preparation methods before colonoscopy remains unknown. This study was conducted to evaluate the patient acceptance of sodium phosphate (NaP) tablets and polyethylene glycol solution (PEG) with sodium picosulfate. METHODS: One hundred patients were randomized into one of the following two groups: the NaP tablet first-use group or the PEG with sodium picosulfate first-use group in a crossover design trial. Patient acceptance and incidence of adverse events were evaluated using a questionnaire. Colon-cleansing effectiveness was also evaluated. RESULTS: Patients' overall impressions of the preparations were significantly different between the NaP tablet (77.9%, 67/86) and PEG with sodium picosulfate (60.5%, 52/86; P = 0.001). Nausea incidence as an adverse event was significantly different between the two regimens (P = 0.03). Colon-cleansing effectiveness was not significantly different between the two regimens. CONCLUSIONS: The results of this crossover study showed that patient acceptance was similar to those previously reported in a parallel-group comparison. In Japanese patients, preference for and acceptance of NaP tablets was significantly higher than that for PEG with sodium picosulfate solution.


Assuntos
Povo Asiático/psicologia , Catárticos/uso terapêutico , Colonoscopia , Aceitação pelo Paciente de Cuidados de Saúde/etnologia , Fosfatos/uso terapêutico , Picolinas/uso terapêutico , Polietilenoglicóis/uso terapêutico , Administração Oral , Adulto , Idoso , Catárticos/administração & dosagem , Catárticos/efeitos adversos , Distribuição de Qui-Quadrado , Citratos , Estudos Cross-Over , Humanos , Incidência , Japão/epidemiologia , Pessoa de Meia-Idade , Náusea/induzido quimicamente , Náusea/etnologia , Compostos Organometálicos , Preferência do Paciente/etnologia , Fosfatos/administração & dosagem , Fosfatos/efeitos adversos , Picolinas/administração & dosagem , Picolinas/efeitos adversos , Polietilenoglicóis/administração & dosagem , Polietilenoglicóis/efeitos adversos , Estudos Prospectivos , Inquéritos e Questionários , Comprimidos
7.
Immunology ; 136(2): 153-62, 2012 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-22236403

RESUMO

Dendritic cells (DCs) are known as antigen-presenting cells and play a central role in both innate and acquired immunity. Peripheral blood monocytes give rise to resident and recruited DCs in lymph nodes and non-lymphoid tissues. The ligands of nuclear hormone receptors can modulate DC differentiation and so influence various biological functions of DCs. The role of bile acids (BAs) as signalling molecules has recently become apparent, but the functional role of BAs in DC differentiation has not yet been elucidated. We show that DCs derived from human peripheral blood monocytes cultured with a BA produce lower levels of interleukin-12 (IL-12) and tumour necrosis factor-α in response to stimulation with commensal bacterial antigens. Stimulation through the nuclear receptor farnesoid X (FXR) did not affect the differentiation of DCs. However, DCs differentiated with the specific agonist for TGR5, a transmembrane BA receptor, showed an IL-12 hypo-producing phenotype. Expression of TGR5 could only be identified in monocytes and was rapidly down-regulated during monocyte differentiation to DCs. Stimulation with 8-bromoadenosine-cyclic AMP (8-Br-cAMP), which acts downstream of TGR5 signalling, also promoted differentiation into IL-12 hypo-producing DCs. These results indicate that BAs induce the differentiation of IL-12 hypo-producing DCs from monocytes via the TGR5-cAMP pathway.


Assuntos
Ácidos e Sais Biliares/imunologia , Células Dendríticas/imunologia , Interleucina-12/imunologia , Leucócitos Mononucleares/imunologia , Receptores Acoplados a Proteínas G/imunologia , 8-Bromo Monofosfato de Adenosina Cíclica/farmacologia , Ácidos e Sais Biliares/metabolismo , Diferenciação Celular/efeitos dos fármacos , Diferenciação Celular/imunologia , Células Cultivadas , Células Dendríticas/metabolismo , Regulação para Baixo , Humanos , Interleucina-12/biossíntese , Leucócitos Mononucleares/metabolismo , Receptores Acoplados a Proteínas G/agonistas , Fator de Necrose Tumoral alfa/biossíntese , Fator de Necrose Tumoral alfa/imunologia
8.
Clin Res Hepatol Gastroenterol ; 36(1): 66-71, 2012 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-22074640

RESUMO

BACKGROUND AND OBJECTIVE: Capsule endoscopy (CE) is a comfortable for the patients; however, CE review is time-consuming. The aim of this study was (1) to evaluate the effectiveness of the CE software in reducing the CE reading time and the number of false negatives by beginners, and (2) to determine the learning curve for reading CE images. METHODS: Capsule endoscopic images were captured by Pillcam SB (Given Imaging Ltd, Tokyo, Japan), and analyzed using the proprietary RAPID 5 software. Comparison of CE reading using different software modes: manual mode, automatic mode, and QuickView (QV) mode. Three trainee endoscopists participated as CE readers. Each participant watched CE videos in which positive findings had been predefined by trained endoscopists. Each participant read the same CE record by using one of three different software modes. These were blinded on clinical history of patients. CE reading time was recorded, and the number of false negatives was counted. Each trainee endoscopist read a total of 45 CE videos, in five steps divided into nine videos per step. RESULTS: There was no significant reader associated difference between the results for the different modes. The QV software did miss some positive findings. Therefore, the total number of instances of FN by the software plus the reader in the QV mode was significantly higher than the others. The reading times in the automatic mode and the QV mode were significantly shorter than that in the manual mode. After the second step, the number of instances of false negatives significantly decreased. CONCLUSIONS: CE software is useful for reducing the reading time. Experience of approximately 20 CE readings can be considered as the first step to becoming an expert.


Assuntos
Endoscopia por Cápsula , Competência Clínica , Educação Médica Continuada/normas , Reações Falso-Negativas , Gastroenteropatias/diagnóstico , Software , Humanos , Japão , Curva de Aprendizado , Fatores de Tempo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...